ReviewFrontiers in immunology2022
Psoriasis and Cardiovascular Diseases: An Immune-Mediated Cross Talk?
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Psoriasis outcomes following metabolic bariatric surgery - a systematic review of the literature.BMC surgery · 2026Pooled it
- Exploring the association between psoriasis and subclinical atherosclerosis defined by carotid intima-media thickness (CIMT) in patients with psoriasis vulgaris: a systematic review and meta-analysis.Irish journal of medical science · 2025Pooled it
- Association between psoriasis and coronary artery calcification: A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2022Pooled it
- Analysis of Clinical Characteristics and Treatment Needs in Elderly Patients with Psoriasis Vulgaris: A Single-Centered Retrospective Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Psoriasis and atrial fibrillation: Exploring the intersection.World journal of experimental medicine · 2025Review
- Treatment Persistence After Major Cardiovascular Events in Psoriasis: A Retrospective Cohort Study Comparing Biologic, Systemic, and Phototherapy.The Journal of dermatology · 2025Article
- Methylarginine Levels in Chronic Inflammatory Skin Diseases-The Role of L-Arginine/Nitric Oxide Pathway.Journal of clinical medicine · 2025Review
- The Association Between Psoriasis, Psoriatic Arthritis, and Fibromyalgia Syndrome: Effects on Treatment-A Population-Based Study.Medicina (Kaunas, Lithuania) · 2025Article
- Cardiovascular and Kidney Outcomes After Systemic Treatment for Plaque Psoriasis: A Systematic Review and Network Meta-analysis.Dermatology and therapy · 2025Article
- Improving Cardiovascular Outcomes in the Psoriasis Cohort. Psoriasis and Cardiovascular Disease-Patient Knowledge, Perspectives and Practice.The Australasian journal of dermatology · 2025Article
- Cardiometabolic Comorbidities of Lichen Planus-A Cross-Sectional Comparative Study.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Improving Cardiovascular Outcomes in the Psoriasis Cohort. Psoriasis and Cardiovascular Disease-Clinician Knowledge, Practice and Perceptions.The Australasian journal of dermatology · 2025Review
- A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system.Scientific reports · 2025Article
- The impact of body mass index on the relationship between psoriasis and Osteopenia: a mediating analysis based on NHANES (2003-2006).Archives of dermatological research · 2025Article
- Elucidating Molecule-Crosstalk of Neutrophil Extracellular Traps Between Cardiovascular Disease and Psoriasis: Insights Into Mendelian Randomization, Single-Cell RNA Analysis, Shared Targets and the Role of Resveratrol.Journal of inflammation research · 2025Article
- A diagnostic prediction model for cardiovascular diseases (CVDs) in patients with psoriasis.Frontiers in cardiovascular medicine · 2025Article
- Overall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients.Frontiers in medicine · 2025Article
- Psoriasis: an emerging risk factor for ischemic stroke?Frontiers in neurology · 2025Review
- Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study.The Journal of dermatology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a chronic immune-mediated inflammatory skin disease, characterized by well-demarcated scaly, erythematous, infiltrated plaques. The cutaneous-to-systemic expansion of the inflammation in psoriasis leads to the concept of "psoriatic march" or "inflammatory skin march". Accordingly, psoriasis is thought to be a systemic inflammatory disease associated with numerous comorbidities. Indeed, it's currently considered an independent risk factor for cardiovascular diseases. Here, we discuss the current knowledge on TNF-α and IL-23/IL-17 mediated pathways linking the psoriatic plaque to the cardiovascular compartment. We further argue the possible involvement of the endothelial compartment in the psoriatic plaque- cardiovascular system crosstalk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.